Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 2/20 | 0.58 |
| ▸ | PLK1 | P53350 | 15/20 | 0.48 |
| ▸ | PLK3 | Q9H4B4 | 2/20 | 0.39 |
| ▸ | KDM6B | O15054 | 1/20 | 0.38 |
| ▸ | KDM4A | O75164 | 1/20 | 0.38 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.38 |
| ▸ | KDM3B | Q7LBC6 | 1/20 | 0.38 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.38 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.38 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.37 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6833718 | 1.00 | ALB (0.58) | ALBPLK1PLK3KDM6BKDM4A | |
| SCHEMBL6814498 | 1.00 | ALB (0.58) | ALBPLK1PLK3KDM6BKDM4A | |
| SCHEMBL6819812 | 1.00 | ALB (0.58) | ALBPLK1PLK3KDM6BKDM4A | |
| SCHEMBL6818796 | 0.99 | ALB (0.59) | ALBPLK1PLK3KDM6BKDM4A | |
| SCHEMBL6834094 | 0.96 | ALB (0.59) | ALBPLK1PLK3AKR1C2AKR1C1 | |
| SCHEMBL6818461 | 0.88 | PLK1 (0.56) | ALBPLK1PLK3KDM6BKDM4A | |
| SCHEMBL6833865 | 0.87 | ALB (0.75) | ALBPLK1PLK3 | |
| SCHEMBL6833308 | 0.87 | ALB (0.75) | ALBPLK1PLK3 | |
| SCHEMBL6830132 | 0.87 | PLK1 (0.51) | ALBPLK1PLK3AKR1C2AKR1C1 | |
| SCHEMBL6818623 | 0.86 | ALB (0.54) | ALBPLK1PLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | claimed |
| WO-2004018428-A1 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | claimed |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | ALB 1417/4885PLK1 4270/4885PLK3 3358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.